Join Growin Stock Community!

Endra life sciences inc.NDRA.US Overview

US StockHealthcare
(No presentation for NDRA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NDRA AI Insights

NDRA Overall Performance

NDRA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NDRA Recent Performance

-6.12%

Endra life sciences inc.

-3.61%

Avg of Sector

-2.16%

S&P500

NDRA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NDRA Key Information

NDRA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NDRA Profile

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Price of NDRA

NDRA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NDRA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.64
PE Ratio (TTM)
0.21
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
28.25
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.64
PE Ratio (TTM)
0.21
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
28.25
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NDRA's latest earnings report released?

    The most recent financial report for Endra life sciences inc. (NDRA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NDRA's short-term business performance and financial health. For the latest updates on NDRA's earnings releases, visit this page regularly.

  • How much debt does NDRA have?

    As of the end of the reporting period, Endra life sciences inc. (NDRA) had total debt of 1.12M, with a debt ratio of 0.57. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NDRA have?

    At the end of the period, Endra life sciences inc. (NDRA) held Total Cash and Cash Equivalents of 794.04K, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NDRA's EPS continuing to grow?

    According to the past four quarterly reports, Endra life sciences inc. (NDRA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NDRA?

    Endra life sciences inc. (NDRA)'s Free Cash Flow (FCF) for the period is -1.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.76% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.